E-santé
Il y a 1 mois
La santé prend cher en ce moment

Dans le monde de la santé, en matière de sécurité des SI – au sens très large du terme –, il s’est passé plus de choses durant les deux dernières années que dans les 20 qui ont précédé.

DSIH
Articles liés par le même flux
Actualité
Il y a 50 minutes
CHU Rouen

Les directives anticipées (DA) sont des documents écrits permettant à toute personne majeure d'exprimer sa volonté, dans le cas où elle serait un jour en incapacité de le faire. L'enjeu principal des DA est de préserver l'autonomie du patient dans ses décisions de fin de vie. L'obj[...]

Actualité
Il y a 50 minutes
CHU Rouen

Selon les pays, il existe différents systèmes permettant aux professionnels de santé et aux patients de déclarer les effets indésirables des médicaments. L'objectif de l'étude était de comprendre comment les patients identifiaient un effet indésirable, leurs réacti[...]

Actualité
Il y a 52 minutes
EFSA

Published on: 21 July 2017

Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and maintenance of long-term normal blood glucose concentration. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Vibigaba. The Panel considers that the germinated brown rice Vibigaba is sufficiently characterised. The claimed effect proposed by the applicant is ‘contribution to the maintenance of normal glycated haemoglobin level’. The Panel considers that maintenance of long-term normal blood glucose concentration is a beneficial physiological effect. The Panel notes that the applicant did not perform a comprehensive literature search to identify human intervention studies whic[...]

Actualité
Il y a 52 minutes
EFSA

Published on: 21 July 2017

Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and reduction of body weight in the context of an energy-restricted diet. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Vibigaba. The Panel considers that the germinated brown rice Vibigaba is sufficiently characterised. The claimed effect proposed by the applicant is ‘in the context of an energy-restricted diet contributes to weight loss’. The Panel considers that reduction of body weight in the context of an energy-restricted diet is a beneficial physiological effect. The Panel notes that the applicant did not perform a comprehensive literature searc[...]

Actualité
Il y a 52 minutes
EFSA

Published on: 21 July 2017

Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood pressure. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Vibigaba. The Panel considers that the germinated brown rice Vibigaba is sufficiently characterised. The claimed effect proposed by the applicant is ‘contribution to the maintenance of normal blood pressure’. The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect. The Panel notes that the applicant did not perform a comprehensive literature search to identify human intervention studies [...]

Actualité
Il y a 1 heures
CHU Rouen

Le diabète est une maladie chronique et fréquente, potentiellement responsable de complications vasculaires sévères. La base de la prise en charge du diabète repose sur l'application des mesures hygiéno-diététiques. Nous avons cherché à évaluer [...]